MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program
Supplemental materials for: Xu-Monette et al
Files in this Data Supplement:
Document 1. Supplemental tables and figure (PDF, 115 KB)